Post by stocksdivas on Feb 29, 2012 14:01:07 GMT -5
NNVC ~ NanoViricides, Inc
NanoViricides, Inc., a nano-biopharmaceutical company, engages in developing drugs for antiviral therapy. The company has licenses to develop drugs for the treatment of human viral diseases, such as H5N1 (avian flu), human influenza, human immunodeficiency virus (HIV/AIDS), hepatitis B virus, hepatitis C virus, herpes simplex virus, and rabies; and dengue viruses, Japanese encephalitis virus, West Nile virus, viruses causing viral conjunctivitis and ocular herpes, and Ebola/Marburg viruses, as well as viral diseases of the eye comprising EKC and herpes keratitis. Its products under pre-clinical development comprise FluCide-I, an anti-influenza nanoviricide for the treatment of common influenzas and avian influenza H5N1; HIVCide, an escape-resistant anti-HIV nanoviricide; Nanoviricide eye drops for the treatment of viral diseases of the external eye; HerpeCide, a skin cream or gel formulation for the treatment of oral and genital herpes lesions; DengueCide, a nanoviricide for the treatment of various types of dengue viruses; RabiCide, an anti-rabies nanoviricide; and Nanoviricide for the treatment of various strains of Ebola and Marburg filoviruses. The company has a license agreement with TheraCour Pharma, Inc. for the development of drug candidates to treat dengue viruses, Ebola/Marburg viruses, Japanese Encephalitis, and viruses causing viral conjunctivitis and ocular herpes. NanoViricides, Inc. is based in West Haven, Connecticut.
NanoViricides, Inc.
135 Wood Street
Suite 205
West Haven, CT 06516
United States - Map
Phone: 203-937-6137
Fax: 203-937-6137
Website: www.nanoviricides.com
www.otcmarkets.com/stock/NNVC/company-info
Management Team
Dr. Eugene Seymour, M.D., MPH has been the Chief Executive Officer of NanoViricides, Inc. since June 8, 2005. Dr. Seymour serves as Chief Financial Officer and Principal Accounting Officer of NanoViricides, Inc. He served as an Interim Chief Financial Officer of NanoViricides Inc. since May 16, 2007. He began clinical practice in Internal Medicine and joined the UCLA Medical School faculty. He Left UCLA after two years and joined USC faculty as Associate Professor. Dr. Seymour served in the Medical Corps of United States Army Reserve during the Vietnam era and attained the rank of Major. He was originally trained as a chemist, but decided to attend medical school in preparation for a career as a clinical investigator. In 1981, he began treating patients with a strange new disease affecting primarily the gay population. He worked with a number of celebrity patients whose identity could not be disclosed for fear of being ostracized in the entertainment community. In 1986, he was requested by the United States government to establish a testing laboratory and run a large-scale surveillance program for HIV prevalence in the Hispanic population in Los Angeles. In 1989, he founded Saliva Diagnostic Systems Inc.and served as its Chief Executive Officer and President since 1993. He left SDS in 1996 to form a non-profit foundation, which funded both testing and training programs for health workers in Asia and Africa. He served as a Consultant to the United Nations Global Program on AIDS and was sent to a number of different countries, (Lithuania, Latvia, Estonia, and Russia) to interact with local physicians and assist them in setting up testing programs. He served as Chairman of the Board of NanoViricides, Inc. since June 8, 2005. He has been Director of NanoViricides, Inc. since June 1, 2005. He served as a Director of Strategic Alliances at a medical education startup called Medschool.com. Dr. Seymour spends his time as a private investor evaluating evolving companies in the field of biotechnology. Dr. Seymour is the holder of 8 issued patents. Following postgraduate medical training, he holds a Master's degree in the Epidemiology of Infectious Diseases at UCLA.
Dr. Anil R. Diwan, Ph.D., has been Chairman of the Board and President of Nanoviricide, Inc. since June 1, 2005. Dr. Diwan has been the Chief Executive Officer of All Excel, Inc. since 1995 and TheraCour Pharma, Inc. since 2004. He is the original inventor of the technologies licensed to NanoViricides Inc., as well as the TheraCour polymeric micelle technologies and products based on them. Since 1992, he has researched and developed TheraCour nanomaterials. Dr. Diwan has extensive product development experience while raising financing from collaborations, SBIR grants, other revenues. He has extensive experience in a number of bio-pharmaceutical, biosciences, and biomedical fields and technologies that leads to his novel, integrative approach in solving problems with low costs, high innovation, and world-leading feature sets. Dr. Diwan is the inventor, developer, and principal investor of TheraCour technologies. The nanomaterials based on these technologies form the basis of nanoviricides drugs. He has over 18 years of Bio-Pharmaceuticals R&D experience with 12 years as an entrepreneur. He has been a Director of All Excel, Inc. since 1995 and of TheraCour Pharma, Inc. since 2004. Dr. Diwan holds a US patent on his older polymeric micelle technologies, with his colleagues at University of Massachusetts. He has continued to work further in the field, to develop nanomaterials that are capable of multi-specific multi-targeting of viruses, and at the same time capable of encapsulating active pharmaceutical ingredients (API) in industry-leading payload capacities. This new work has resulted in nanomaterials called 'TheraCour' (therapeutic courier), and the underlying technology is subject of a new patent application. Multi-targeting allows binding to the virus particle like a Velcro tape, and Multi-specificity allows highly selective binding to a specific type of virus. The encapsulated API can get injected into the virus particle. Dr. Diwan has held several scholastic distinctions, including an All-India 9th rank on the Joint Entrance Examination of all IIT's. Dr. Diwan holds a Ph.D. in Biochemical Engineering from Rice University, TX in 1986, and B.S. degree in Chemical Engineering from Indian Institute of Technology (IIT) Bombay in 1980 and has consistently held high scholastic ranks and honors.
www.nanoviricides.com/aboutus.html
Pipeline
www.nanoviricides.com/pipeline.html
NanoViricides, Inc. is a nano-biopharmaceutical company whose business goals are to discover, develop and commercialize therapeutics (nanoviricides™) to advance the care of patients suffering from life-threatening viral infections.
NanoViricides, Inc. is a development stage company. The Company's novel nanoviricide™ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal influenza, HIV, Epidemic Kerato-Conjunctivitis (EKC), hepatitis C, rabies, dengue fever, and Ebola virus, among others.
NanoViricides, Inc., a nano-biopharmaceutical company, engages in developing drugs for antiviral therapy. The company has licenses to develop drugs for the treatment of human viral diseases, such as H5N1 (avian flu), human influenza, human immunodeficiency virus (HIV/AIDS), hepatitis B virus, hepatitis C virus, herpes simplex virus, and rabies; and dengue viruses, Japanese encephalitis virus, West Nile virus, viruses causing viral conjunctivitis and ocular herpes, and Ebola/Marburg viruses, as well as viral diseases of the eye comprising EKC and herpes keratitis. Its products under pre-clinical development comprise FluCide-I, an anti-influenza nanoviricide for the treatment of common influenzas and avian influenza H5N1; HIVCide, an escape-resistant anti-HIV nanoviricide; Nanoviricide eye drops for the treatment of viral diseases of the external eye; HerpeCide, a skin cream or gel formulation for the treatment of oral and genital herpes lesions; DengueCide, a nanoviricide for the treatment of various types of dengue viruses; RabiCide, an anti-rabies nanoviricide; and Nanoviricide for the treatment of various strains of Ebola and Marburg filoviruses. The company has a license agreement with TheraCour Pharma, Inc. for the development of drug candidates to treat dengue viruses, Ebola/Marburg viruses, Japanese Encephalitis, and viruses causing viral conjunctivitis and ocular herpes. NanoViricides, Inc. is based in West Haven, Connecticut.
NanoViricides, Inc.
135 Wood Street
Suite 205
West Haven, CT 06516
United States - Map
Phone: 203-937-6137
Fax: 203-937-6137
Website: www.nanoviricides.com
www.otcmarkets.com/stock/NNVC/company-info
Management Team
Dr. Eugene Seymour, M.D., MPH has been the Chief Executive Officer of NanoViricides, Inc. since June 8, 2005. Dr. Seymour serves as Chief Financial Officer and Principal Accounting Officer of NanoViricides, Inc. He served as an Interim Chief Financial Officer of NanoViricides Inc. since May 16, 2007. He began clinical practice in Internal Medicine and joined the UCLA Medical School faculty. He Left UCLA after two years and joined USC faculty as Associate Professor. Dr. Seymour served in the Medical Corps of United States Army Reserve during the Vietnam era and attained the rank of Major. He was originally trained as a chemist, but decided to attend medical school in preparation for a career as a clinical investigator. In 1981, he began treating patients with a strange new disease affecting primarily the gay population. He worked with a number of celebrity patients whose identity could not be disclosed for fear of being ostracized in the entertainment community. In 1986, he was requested by the United States government to establish a testing laboratory and run a large-scale surveillance program for HIV prevalence in the Hispanic population in Los Angeles. In 1989, he founded Saliva Diagnostic Systems Inc.and served as its Chief Executive Officer and President since 1993. He left SDS in 1996 to form a non-profit foundation, which funded both testing and training programs for health workers in Asia and Africa. He served as a Consultant to the United Nations Global Program on AIDS and was sent to a number of different countries, (Lithuania, Latvia, Estonia, and Russia) to interact with local physicians and assist them in setting up testing programs. He served as Chairman of the Board of NanoViricides, Inc. since June 8, 2005. He has been Director of NanoViricides, Inc. since June 1, 2005. He served as a Director of Strategic Alliances at a medical education startup called Medschool.com. Dr. Seymour spends his time as a private investor evaluating evolving companies in the field of biotechnology. Dr. Seymour is the holder of 8 issued patents. Following postgraduate medical training, he holds a Master's degree in the Epidemiology of Infectious Diseases at UCLA.
Dr. Anil R. Diwan, Ph.D., has been Chairman of the Board and President of Nanoviricide, Inc. since June 1, 2005. Dr. Diwan has been the Chief Executive Officer of All Excel, Inc. since 1995 and TheraCour Pharma, Inc. since 2004. He is the original inventor of the technologies licensed to NanoViricides Inc., as well as the TheraCour polymeric micelle technologies and products based on them. Since 1992, he has researched and developed TheraCour nanomaterials. Dr. Diwan has extensive product development experience while raising financing from collaborations, SBIR grants, other revenues. He has extensive experience in a number of bio-pharmaceutical, biosciences, and biomedical fields and technologies that leads to his novel, integrative approach in solving problems with low costs, high innovation, and world-leading feature sets. Dr. Diwan is the inventor, developer, and principal investor of TheraCour technologies. The nanomaterials based on these technologies form the basis of nanoviricides drugs. He has over 18 years of Bio-Pharmaceuticals R&D experience with 12 years as an entrepreneur. He has been a Director of All Excel, Inc. since 1995 and of TheraCour Pharma, Inc. since 2004. Dr. Diwan holds a US patent on his older polymeric micelle technologies, with his colleagues at University of Massachusetts. He has continued to work further in the field, to develop nanomaterials that are capable of multi-specific multi-targeting of viruses, and at the same time capable of encapsulating active pharmaceutical ingredients (API) in industry-leading payload capacities. This new work has resulted in nanomaterials called 'TheraCour' (therapeutic courier), and the underlying technology is subject of a new patent application. Multi-targeting allows binding to the virus particle like a Velcro tape, and Multi-specificity allows highly selective binding to a specific type of virus. The encapsulated API can get injected into the virus particle. Dr. Diwan has held several scholastic distinctions, including an All-India 9th rank on the Joint Entrance Examination of all IIT's. Dr. Diwan holds a Ph.D. in Biochemical Engineering from Rice University, TX in 1986, and B.S. degree in Chemical Engineering from Indian Institute of Technology (IIT) Bombay in 1980 and has consistently held high scholastic ranks and honors.
www.nanoviricides.com/aboutus.html
Pipeline
www.nanoviricides.com/pipeline.html
NanoViricides, Inc. is a nano-biopharmaceutical company whose business goals are to discover, develop and commercialize therapeutics (nanoviricides™) to advance the care of patients suffering from life-threatening viral infections.
NanoViricides, Inc. is a development stage company. The Company's novel nanoviricide™ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal influenza, HIV, Epidemic Kerato-Conjunctivitis (EKC), hepatitis C, rabies, dengue fever, and Ebola virus, among others.